DARIEN, CT., March 26, 2014 -- Robert F. Kaiko, Ph.D. recently joined Cytogel Pharma as a scientific and clinical advisor on the development of its novel analgesic, an endomorphin named Cyt-1010. We are most pleased to have Dr. Kaiko join our team, stated Dean Maglaris, Cytogel CEO. We are looking forward to moving into Phase 2 clinical trials to further demonstrate the important advantages of Cyt-1010 in terms of analgesic activity and safety from the serious side effects seen with other opioids.
Dr. Kaiko spent over 28 years at Purdue Pharma, formerly The Purdue Frederick Company, serving as associate medical director, vice president of clinical research and vice president, R&D portfolio development. He was instrumental in the clinical development of controlled-release oral morphine (MS Contin), controlled-release oral oxycodone (OxyContin) and its recent reformulation, and initiated the clinical development of transdermal buprenorphine (BuTrans). Dr. Kaiko is an inventor on a number of patents on opioid analgesia and has published 100 peer reviewed articles and almost 200 abstracts.
Dr. Kaiko served on the board of Pain and Analgesia and PRN Forum, was a contributing editor for the Journal of Pain and Symptom Management and Cancer Pain Release and was a reviewer for the Journal of Pharmaceutical Sciences and several other research publications. He has also served as president and board member of the Eastern Pain Association. Dr. Kaiko has consulted for the Food and Drug Administration, the Drug Abuse Advisory Board, the Federal Trade Commission, and the World Health Organization. He was also a grant reviewer and site visitor for the National Cancer Institute and the Veteran's Administration.
Dr. Kaiko received a bachelor's degree from the University of Connecticut School of Pharmacy (1970) and a Ph.D. in pharmacology from Cornell University Graduate School of Biomedical Sciences in New York City (1974). He has been a research associate at Sloan-Kettering Institute for Cancer Research in the Analgesic Studies Section and also a postdoctoral research fellow, instructor and adjunct assistant professor at Cornell University Graduate School of Biomedical Sciences in the Department of Pharmacology.
About Cytogel Pharma
Cytogel Pharma, LLC. is a biopharmaceutical development company based in Darien, Connecticut, focused on developing promising early-stage programs that offer significant potential both as platform technologies and high value product candidates. The company's primary focus is currently on its novel and proprietary analgesic product candidate, Cyt-1010. Cytogel will develop products to the point of demonstrated value and then license these products to other larger companies for the full development and subsequent commercialization. To learn more about Cytogel, please visit our website at www.cytogelpharma.com.